William Smith

A Modest Proposal to Raise Federal Revenue

/in , , , /by William Smith
Share on Facebook
Share on Twitter
Share on
LinkedIn
+

This op-ed originally appeared in the Washington Examiner on September 25th, 2021

As a way to tackle drug prices, President Joe Biden recently announced that he supports the so-called “inflation rebate,” which would require drug companies to give the federal government any revenue from Medicare drug prices above the general rate of inflation. Senate Finance Committee Chairman Ron Wyden and House Speaker Nancy Pelosi have also publicly endorsed the inflation rebate.

Given the struggles of the Democrats in raising revenue for their $3.5 trillion spending lollapalooza, why limit the inflation rebate to prescription drugs? If this inflation rebate is such a clever idea, why not raise revenue by also taxing excessive price increases on everything purchased or subsidized by the government?

Let’s start with Wyden, an Oregon Democrat. According to Wells Fargo analysts, the price for a standard 1,000 board feet of lumber jumped from $347 to $1,645 between May 2020 and 2021. Why shouldn’t the Oregon timber industry be required to rebate some of the revenue it secured above the inflation rate?

After all, the federal government is going to end up subsidizing the purchase of a great deal of lumber with all this new federal infrastructure spending, and the federal government also funds the construction of lots of affordable housing. Let’s total up all federal spending or subsidies for lumber and then send the timber industry an invoice if its prices have exceeded inflation.

And what about beef? Between February 2020 and June 2021, beef and veal prices soared 13.2%. Arizona has a very robust beef industry. Where is the proposal from Sen. Mark Kelly, an Arizona Democrat, to require the beef industry to rebate the excess revenues they have secured above the inflation rate?

After all, the federal government buys lots of beef through the Supplemental Nutrition Assistance Program and other food assistance programs. The SNAP alone purchased $80 billion in food last year, and this does not include any beef that may have been purchased by the military or other agencies. The beef industry should be invoiced and rebate some of its profits to the taxpayer.

Let’s not forget the Republicans. Corn prices have risen 50% in 2021 as the price of a bushel of corn has doubled in the past year. Where is the proposal from Sen. Chuck Grassley of Iowa to enact a corn inflation rebate? Let’s make our expensive federal food assistance programs more affordable with an inflation rebate on any corn products purchased by these programs. Moreover, the federal government requires consumers to purchase gasoline containing corn ethanol, which climbed in price by 63% in 2021. Let’s help consumers with rising gas prices by requiring an inflation rebate on ethanol price increases, funds that could be used to lower federal gas taxes.

Finally, for his entire career, Sen. Bernie Sanders of Vermont has worked to keep U.S. dairy prices high. Dairy prices have not risen during the pandemic, probably because many schools were closed. But as they reopen, milk prices could surge. Sanders could prove his bona fides by enacting an inflation rebate on dairy products to preempt future price increases. After all, if milk prices start to soar in the future, we should protect those school lunch programs, which cost the taxpayers over $14 billion, from higher costs. The $80 billion SNAP program probably pays for lots of milk, and so does the Defense Department. So let’s send a rebate invoice to the dairy industry if prices rise too fast.

Think of the revenue that could be secured by the federal government if all essential commodities purchased or subsidized by the government were subject to an inflation rebate. Shouldn’t there have been an inflation rebate applied to the F-35 program? The federal government is the largest purchaser of goods and services in the world, so let’s apply the inflation rebate to everything the federal government purchases: software, gasoline, jet fuel, weapons, automobiles, concrete, equipment, and on and on.

Would any of these senators ever apply the inflation rebate to their home-state industries? Of course not. From an economic perspective, it is a ludicrous idea, as prices are determined by markets, supply and demand, and other complex factors. They would only weaken their home-state industries with such a law. But they are happy to selectively apply the farcical inflation rebate to the unpopular drug industry.

The hypocrisy inflation rate is surging in Washington, D.C.

William Smith, Ph.D., is a visiting fellow in life sciences at Pioneer Institute in Boston.

 

Get Updates On Our Life Sciences Work!

Opinion: Legislature should act on bill to limit out-of-pocket drug costs

S. 609, a bill that would limit out-of-pocket costs for patients paying for prescription drugs, is a clear step in the right direction. Massachusetts should join 16 other states that have passed similar bills to protect patients.

Opinion: Drug patents aren’t a ‘necessary evil.’ They save lives.

Drug patents are one of the most important public policy innovations in all of human history, and a boon to patients awaiting cures. Inventions only come when inventors are rewarded, not punished. Patents are not a “necessary evil.”

A Federal Drug Discount Program for the Wealthy

The combination of legal disputes, a growing data repository and investigative reports have necessarily put the 340B Drug Pricing Program under the microscope. Combined with the fact that the policy lacks transparency, 340B has spiraled out of control to the point that no policymaker can ignore the need to look closer.

Harvard research points to ending drug cost help

A common grievance about Harvard is that the university is out of touch with the concerns of everyday Americans. This perception is confirmed by recent research from Harvard Business School that contends patients should be denied assistance that helps them afford their prescription drugs. The Harvard study argues that in order to control drug prices, the government should deny patients’ access to copay assistance programs offered by drug manufacturers. It flies in the face of federal and state efforts to protect the value of such assistance programs for patients and ignores basic facts about how and when patients use copay assistance to access their medications.

A Modest Proposal to Raise Federal Revenue

As a way to tackle drug prices, President Joe Biden recently announced that he supports the so-called “inflation rebate,” which would require drug companies to give the federal government any revenue from Medicare drug prices above the general rate of inflation. Senate Finance Committee Chairman Ron Wyden and House Speaker Nancy Pelosi have also publicly endorsed the inflation rebate.

Why are health care costs rising every year in Massachusetts?

0 Comments
/
The largest driver is the increase in prices by health systems that have the clout to command higher payments and work to recruit more patients to their high-cost facilities.

A Rush to Judgment on Alzheimer’s Drug

0 Comments
/
The Boston-based Institute for Clinical and Economic Review (ICER) sells itself as an independent source of information on the value of pharmaceuticals. But earlier this month, their bias was again evident when they tried to kneecap a drug for a dreaded disease before there’s even enough data to determine how valuable the drug really is. ICER has adopted this same strategy in the past on innovative drugs for cancer, cystic fibrosis, and other devastating diseases. This time ICER’s target is aducanumab, Biogen’s drug for Alzheimer’s disease.

ICER Proves Its Lack of Business Acumen, Again

0 Comments
/
A recent Institute for Clinical and Economic Review (ICER) “Report on Unsupported Price Increases,” concluded that: “Among the top drugs with price increases in 2019…ICER determined that seven of 10 lacked adequate new evidence to demonstrate a substantial clinical benefit that was not yet previously known.”  The impression left by the report is that drug companies arbitrarily raise prices without good reason.  As with so many ICER products, the study is misleading and demonstrates a profound lack of business acumen.